Cellular Interference in Craniofrontonasal Syndrome: Males Mosaic for Mutations in the X-Linked EFNB1 Gene Are More Severely Affected than True Hemizygotes

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.1093/hmg/ddt015

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:10622989

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Cellular interference in craniofrontonasal syndrome: males mosaic for mutations in the X-linked \textit{EFNB1} gene are more severely affected than true hemizygotes

Stephen R.F. Twigg\textsuperscript{1}, Christian Babbs\textsuperscript{1}, Marijke E.P. van den Elzen\textsuperscript{3}, Anne Goriely\textsuperscript{1}, Stephen Taylor\textsuperscript{2}, Simon J. McGowan\textsuperscript{2}, Eleni Giannoulatou\textsuperscript{1,2}, Lorne Lonie\textsuperscript{5}, Jiannis Ragoussis\textsuperscript{6}, Elham Sadighi Akha\textsuperscript{6}, Samantha J.L. Knight\textsuperscript{6}, Roseli M. Zechi-Ceide\textsuperscript{7}, Jeannette A.M. Hoogboom\textsuperscript{4}, Barbara R. Pober\textsuperscript{8}, Helga V. Toriello\textsuperscript{9}, Steven A. Wall\textsuperscript{10}, M. Rita Passos-Bueno\textsuperscript{11}, Han G. Brunner\textsuperscript{12}, Irene M.J. Mathijssen\textsuperscript{3} and Andrew O.M. Wilkie\textsuperscript{1,10,}\textsuperscript{*}

\textsuperscript{1}Clinical Genetics, \textsuperscript{2}Computational Biology Research Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, \textsuperscript{3}Department of Plastic and Reconstructive Surgery, \textsuperscript{4}Department of Clinical Genetics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands, \textsuperscript{5}The Genomics Group, \textsuperscript{6}NIHR Biomedical Research Centre Oxford, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK, \textsuperscript{7}Department of Clinical Genetics, Hospital of Rehabilitation and Craniofacial Anomalies, University of São Paulo, São Paulo, Brazil, \textsuperscript{8}Department of Pediatrics, Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA, \textsuperscript{9}College of Human Medicine, Michigan State University, Grand Rapids, MI, USA, \textsuperscript{10}Craniofacial Unit, Oxford University Hospitals NHS Trust, Oxford, UK, \textsuperscript{11}Centro de Estudos do Genoma Humano, Instituto de Biociências, Universidade de São Paulo, São Paulo, Brazil and \textsuperscript{12}Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Received December 6, 2012; Revised and Accepted January 14, 2013

Craniofrontonasal syndrome (CFNS), an X-linked disorder caused by loss-of-function mutations of \textit{EFNB1}, exhibits a paradoxical sex reversal in phenotypic severity: females characteristically have frontonasal dysplasia, craniosynostosis and additional minor malformations, but males are usually more mildly affected with hypertelorism as the only feature. X-inactivation is proposed to explain the more severe outcome in heterozygous females, as this leads to functional mosaicism for cells with differing expression of EPHRIN-B1, generating abnormal tissue boundaries—a process that cannot occur in hemizygous males. Apparently challenging this model, males occasionally present with a more severe female-like CFNS phenotype. We hypothesized that such individuals might be mosaic for \textit{EFNB1} mutations and investigated this possibility in multiple tissue samples from six sporadically presenting males. Using denaturing high performance liquid chromatography, massively parallel sequencing and multiplex-ligation-dependent probe amplification (MLPA) to increase sensitivity above standard dideoxy sequencing, we identified mosaic mutations of \textit{EFNB1} in all cases, comprising three missense changes, two gene deletions and a novel point mutation within the 5′ untranslated region (UTR). Quantification by Pyrosequencing and MLPA demonstrated levels of mutant cells between 15 and 69%. The 5′ UTR variant mutates the stop codon of a small upstream open reading frame that, using a dual-luciferase reporter construct, was demonstrated to exacerbate interference with translation of the wild-type protein. These results demonstrate a more severe outcome in mosaic than in constitutionally deficient males in an X-linked dominant disorder and provide further support for the cellular interference mechanism, normally related to X-inactivation in females.

\textsuperscript{*}To whom correspondence should be addressed at: Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK. Tel: +44 1865222619; Fax: +44 1865222500; Email: andrew.wilkie@imm.ox.ac.uk

© The Author 2013. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permission@oup.com
INTRODUCTION

Craniofrontonasal syndrome [CFNS (MIM 304110)] is a rare, X-linked disorder in which heterozygous females paradoxically account for the majority of cases and are more severely affected than hemizygous males. CFNS constitutes a specific cause of frontonasal malformation (1,2), in which females typically have severe hypertelorism with a grooved nasal tip, synostosis of the coronal sutures (unilateral or bilateral), craniofacial asymmetry, downslanting palpebral fissures, fine frizzy hair, abnormal scapular development (Sprengel shoulder), partial cutaneous syndactyly of the hands and feet and longitudinal ridging of the nails. Less frequent features include cleft lip + palate, duplication of the thumbs or halluces, partial or complete agenesis of the corpus callosum and learning disability (3,4). In contrast, males are usually more mildly affected with a non-specific phenotype of hypertelorism and occasional cleft lip (2,5–7) (Fig. 1A).

The exclusive, or disproportionately, female-restricted phenotypic expression in dominantly inherited X-linked disorders can be caused either by male lethality, typified by diseases such as oral-facial-digital syndrome type 1, incontinentia pigmenti and Rett syndrome, or, very rarely, to male sparing, described, to our knowledge, in only two disorders: infantile epileptic encephalopathy caused by mutations in PCDH19 (8,9), and CFNS caused by mutations in EFNBI (10,11). The explanation for the sex bias in disease manifestation, whereby heterozygous females are paradoxically more severely affected than hemizygous males, is proposed to be related to a combination of (i) random X-inactivation occurring in females, rendering them mosaic, (ii) the specific roles of these genes (which are normally subjected to X-inactivation) in cell surface properties, causing abnormal cellular interactions in the mosaic state and (iii) the presumed functional redundancy of the gene in the non-mosaic hemizygous male. This unusual mechanism has been termed cellular interference (12), a name originating from the earlier hypothesis of metabolic interference (13).

The cellular interference mechanism is difficult to test in humans, and previous studies of females with CFNS carrying confirmed EFNBI mutations did not demonstrate any correlation between clinical severity and either the extent or direction of skewing of X-inactivation (10) or in the case of females exhibiting somatic mosaicism, the level of mutational mosaicism in somatic tissues (14). However, studies of mice are strongly supportive of cellular interference. Female mice heterozygous for a loss-of-function allele (Efnbi<sup>+/−</sup>) exhibit polydactyly, a phenotype not observed in either hemizygous male (Efnbi<sup>−/−</sup>) or homozygous female (Efnbi<sup>−/−</sup>) mutants. This phenotype could be related to the formation of patches of ephrin-b1 expressing and non-expressing cells that exhibited down- and up-regulation, respectively, of the cognate cell-surface receptors EphB2, EphB3 and EphA4 (15,16). Using an X-linked green-fluorescent protein transgene, it was shown that the patch boundaries corresponded exactly to those for the X-inactivation pattern; however, the patch sizes were much larger than those normally generated by X-inactivation indicating an active homotypic cell sorting process (15). Further studies of Efnbi<sup>+/−</sup> heterozygous mice have shown patchy expression of ephrin-b1 in additional tissues, including calvaria and palate, and related this to perturbation in downstream signalling (17,18).

In humans, although the classical CFNS phenotype is almost entirely restricted to females, very occasionally 46,XY males present in a similar fashion. To date, there are only two convincing case reports (19,20) (both subjects are analysed here), but we describe in addition a further four previously unpublished cases. After ruling out alternative explanations such as 46,XX sex reversal, one possible interpretation for this phenomenon, based on the cellular interference hypothesis, could be postzygotic mosaicism for the mutation. To investigate this further, we have scrutinized EFNBI for mosaic mutations in these six sporadically affected CFNS males. Here, we report the identification of mosaic EFNBI mutations in every individual, confirming the suggested diagnosis and supporting the hypothesis of cellular interference in humans. Moreover, in one case, we identified an unusual mutation of an upstream open reading frame (uORF) on which we undertook further functional studies, demonstrating that this interferes with translation of the ORF encoding EPHRIN-B1.

RESULTS

Subjects

Six severely affected sporadic males with a diagnosis of CFNS were identified; Subjects 3269 and 4021 are the cases previously reported by Kapusta et al. (20) and Kwee and Lindhout (19) respectively, and the remainder represent previously unpublished cases. In an earlier study, we had analysed EFNBI in two of these individuals (Subjects 3269 and 1330), but did not identify causative mutations (14).

The clinical features of the six males are summarized in Table 1 and illustrated in Figure 1B–G, in which their more severe dysmorphic features are evident when compared with affected male offspring of females with CFNS, who are obligate carriers of the EFNBI mutation (Fig. 1A). All six subjects had documented coronal craniosynostosis, and all exhibited severe hypertelorism. Other characteristic features not found in CFNS obligate carrier males included bifid nasal tip and longitudinally split nails. Some individuals had additional significant phenotypes, including undescended testes and mild learning disability.

Mosaic point mutations of EFNBI in males with CFNS

Initially, we attempted to identify mosaic mutations in the coding region of EFNBI by WAVE denaturing high performance liquid chromatography (DHPLC), as we have previously shown that this is more sensitive than dideoxy sequencing for the detection of low levels of mutant alleles (14). Our original series comprised three male CFNS cases (Subjects 3269, 1330 and 4021; Fig. 1B–D), from whom we analysed DNA extracted from multiple tissue samples (blood, buccal scrapings and hair roots) because the level of mosaicism might vary depending on the timing and tissue origin of the mutation. In Subject 3269, a subtly abnormal WAVE DHPLC trace was detected in exon 2 of EFNBI, and dideoxy sequencing identified a corresponding point mutation, c.496C > T, encoding the nonsense change p.Q166* (Fig. 2A). This mutation, previously described in a mildly affected hemizygous father and his two daughters with classical CFNS (14,20), was confirmed...
by restriction digest, and the level of mosaicism quantified by Pyrosequencing. Different proportions of the mutant $EFNB1$ allele (27 and 35%) were present in buccal scrapings and blood, respectively (Fig. 2A).

Our screening strategy did not, however, identify mutations in Subjects 1330 and 4021. Because this could be due to low levels of mutant allele in available tissues or the mutations were located outside the coding sequences screened, we undertook massively parallel sequencing (MPS) of a 13.7 kb genomic region including the entire $EFNB1$ gene in both subjects, together with a newly ascertained CFNS male in whom we did not undertake prior dideoxy sequencing (Subject 4271, Fig. 1E). We sequenced pooled PCR products from all available tissue samples and generated over 5 million 36 bp reads, 82% of which mapped to $EFNB1$, with an average sequence depth of 6900-fold (Supplementary Material, Fig. S1). Variants were ranked according to the percentage of reads with a variant base at any given position (Supplementary Material, Table S2); 97 variants had a frequency of $\geq 1\%$. The top 18 hits were accounted for by single nucleotide polymorphisms (SNPs), all but one of which were documented in dbSNP (a single C/$-$ SNP accounted for 2 hits). The 19th variant call, c.$-95T \rightarrow G$ in the 5′ untranslated region (UTR), had eluded our previous screen of $EFNB1$ because it lay outside the coding region. The c.$-95T \rightarrow G$ mutation was found to originate from Subject 1330, who exhibited variable levels of mosaicism (19–54%) in different tissues (Fig. 2B). The mutation was absent in the subject’s unaffected mother, establishing that it had arisen de novo and was also absent in 386 normal controls. Further supporting the likely pathogenicity of this change, we identified a mosaic c.$-95T \rightarrow C$ mutation at the same nucleotide in a female with classical CFNS (Supplementary Material, Fig. S2A). Additional functional investigation of the pathogenicity of the c.$-95T \rightarrow G$ variant is described in the final section of the Results.

Further scrutiny of data from the MPS experiment revealed five changes within the $EFNB1$ coding sequence (Supplementary Material, Table S2). One of these, c.$196C \rightarrow T$ in exon 2 encoding p.R66*—a recurrent nonsense mutation previously identified in 12 CFNS families (10,14,21,22) —was confirmed by dideoxy sequencing, restriction digest and Pyrosequencing to be mosaic (46–69%) and de novo in Subject 4271 (Fig. 1E). We followed up the other potential coding sequence changes from the MPS experiment, using a combination of dideoxy

Figure 1. Clinical features of males hemizygous for $EFNB1$ mutations (A) and mosaic males analysed in this study (B–G). (A) Previously published males (14,32) with $EFNB1$ mutations. The individuals shown are the offspring of females carrying $EFNB1$ mutations, indicating that all these males are fully hemizygous; this was confirmed by restriction digest and/or sequencing of DNA isolated from peripheral blood. Note mild facial features of these individuals, who exhibit hypertelorism, but not craniosynostosis. (B–G) Males diagnosed with CFNS (pre-operative images unless stated). Common features include coronal craniosynostosis [three-dimensional computed tomographic skull reconstructions in Subject 4354 (F) shows a patent right coronal suture (black arrow), but the left coronal suture is absent (red arrow) and instead there is a bony ridge; Subject 3301 (G) has a large ossification defect in the position of the metopic suture (arrowhead) and coronal craniosynostosis], craniofacial asymmetry [shown most clearly in the top view in (C)], hypertelorism, downslanting palpebral fissures and broad nasal roots with bifid nasal tips. Wiry hair is also present in most cases. Subject 1330 also presented with unilateral cleft lip (C) and Subject 4021 with duplex thumbs (D).
Table 1. Clinical features of CFNS males with mosaic EFNB1 mutations

<table>
<thead>
<tr>
<th>Subject</th>
<th>Hypertelorism</th>
<th>Downslanting</th>
<th>Cleft lip or palate</th>
<th>ACC</th>
<th>Learning disability</th>
<th>Other features</th>
<th>Low palate anomaly</th>
<th>Profuse sweating</th>
<th>Vertebral anomalies</th>
<th>Other features</th>
</tr>
</thead>
<tbody>
<tr>
<td>3269</td>
<td>r</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1310</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4021</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4271</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4354</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3301</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Mosaic deletions of EFNB1 in males with CFNS

As we were unable to detect point mutations or small indels in Subjects 4021 and 3301, we next carried out multiplex-ligation-dependent probe amplification (MLPA) on DNA from all available tissues to determine if there was mosaicism for a deletion of part or all of EFNB1. In Subject 3301, a sample of blood DNA demonstrated complete deletion of all 5 exons of EFNB1 in 39.5% of cells, based on the relative reduction in heights of the MLPA peaks when compared with male controls (Fig. 2E). The deletion was confirmed by hybridization of DNA to a SNP microarray using the Illumina HumanCytosNP12 BeadChip (∼300 k), suggesting a deletion size of ∼137–211 kb and possible overlap with the 3′ end of the neighbouring gene, STARD8 (Supplementary Material, Fig. S3). MLPA analysis of blood DNA from Subject 4021 suggested a low level mosaic deletion of EFNB1 exons 3–5 in 17.4% of cells (Fig. 2E). As this finding was near the sensitivity limit of MLPA, we used inverse PCR to support this result by isolating a specific breakpoint product. This confirmed that there was a deletion of 8391 bp in the patient sample; there was a 4 bp microhomology at the two breakpoints, suggestive of repair by non-homologous end joining (Fig. 2F). As the deletion extended beyond the region amplified by long PCR in the MPS experiment, it would not have been represented in the sequencing products that we had analysed.

Mutations at nucleotide-95 locate in an uORF and abrogate translation

As described above, Subject 1330 was mosaic for a 95T > G substitution, and we identified a mosaic c.95T > C change in a female with CFNS. Both mutations are predicted to abolish the stop codon of a short (4 codons) uORF, with the effect of elongating the predicted translation product to overlap by 44 codons (in a different frame) with that of the main EFNB1 translation product. Because uORFs have been implicated both in normal regulation of expression and in disease states (24,25), we decided to investigate this further by exploring evolutionary conservation and undertaking experimental studies.
Analysis of \( \text{EFNB1} \) orthologues in a variety of vertebrates revealed unequivocal homologues of the uORF in all mammalian sequences, including evolutionarily ancient placental mammals (hyrax and armadillo) and marsupials (wallaby). A similar uORF is also present in chicken and zebra finch. The most divergent upstream sequences from zebrafish and \( \text{Xenopus} \) contain longer uORFs (nine and seven codons, respectively), and downstream of the zebrafish uORF, an in-frame ATG is present (Fig. 3A). This high degree of sequence homology is suggestive of conserved function, at least in birds and mammals. The human \( \text{EFNB1} \) main ORF and uORF translation start sequences are almost identical, and both fit with the Kozak consensus sequence for translation efficiency (Fig. 3B).

As uORFs commonly modulate translation of downstream ORFs (dORFs) (25), we investigated whether the c. \(-95T>G\) mutation affected EPHRIN-B1 production. We first confirmed that the mutant allele was expressed in Subject 1330 (Supplementary Material, Fig. S2B), excluding any major negative regulatory effect on transcription. Using a previously described dual luciferase reporter construct to measure translational output (25), we found a significant reduction in translation from the main dORF in the presence of c. \(-95T>G\) (Fig. 3). This inhibition was completely reversed to the wild-type (wt) level by introducing a stop at the next codon. Finally, when the uORF start codon was mutated in the context of the c. \(-95T>G\) variant, translation of the dORF was increased to a level significantly higher than for the wt sequence, suggesting that the uORF is a physiologically acting negative regulator of \( \text{EFNB1} \) translation and that abolition of the stop codon by the c. \(-95T>G\) mutation accentuates this negative effect.

DISCUSSION

Males with classical CFNS features appear not to fit with the cellular interference model for pathogenesis of this X-linked disorder, whereby females are severely affected because of a functionally mosaic state caused by X-inactivation, but
males are spared because of redundancy in the essential functions of EFNB1. We investigated this problem by studying six males, all with CFNS phenotypes resembling those in females. We hypothesized that, if cellular interference is the mechanism responsible for development of classical CFNS, an analogous situation could arise in males, if they were somatically mosaic for mutation of EFNB1. To improve the chances of detecting a mosaic mutation, we collected as many tissue samples as possible for each individual and analysed these by a number of different techniques (DHPLC, MPS and MLPA) to increase sensitivity above dideoxy sequencing. Ultimately, we detected pathogenic, mosaic mutations in all six males with mosaicism for larger rearrangements of the X chromosome that include normally functioning copies. Analogous to the situation in females, where heterozygous duplication of the EFNB1 gene copy [karyotype 46,XY/47,XY,r(X)], the affected individual exhibited several clinical features suggestive of CFNS, and the authors of the paper noted several other reminiscent, but less well-characterized cases in older literature (27).

We sampled cells of different embryonic lineages (buccal—endoderm, peripheral blood—mesoderm and hair root—ectoderm), finding that mutational mosaicism was present in all lineages and that it attained relatively high levels (ranging from 15 to 69%). This suggests that the mosaicism arose at a totipotent stage of development within the first few cell divisions of the embryo, most likely by post-zygotic mutation—although back mutation of a zygotic error cannot be formally excluded. Hence, these events may occur slightly earlier than functional mosaicism in females arising from X-inactivation that initiates around the eight-cell stage (28). Nevertheless, the phenotypic outcomes in the two sexes appear equivalent, probably because the abnormal developmental processes leading to the CFNS phenotype involve later tissue patterning and result in similarly sized mosaic patches. Supporting the concept that relatively high level mosaicism is required to develop the full CFNS phenotype, the one previously described male mosaic for EFNB1 mutation, who had low levels of mutation both in blood (3%) and hair roots (2%), only manifested the mild features associated with the male carrier state (14).

As part of this work, we identified a novel mechanism of CFNS pathogenesis, involving the predicted translational read-through of a conserved uORF, leading to repression of translation of EFNB1 from the main dORF. uORFs occur in approximately 140 bp upstream of the start codon. A further uORF found in chicken is also boxed, as are the larger uORFs found in the Xenopus and zebrafish upstream sequences. The zebrafish sequence includes an upstream ATG (underlined) that is in frame with the dORF. Sixteen amino acids of the wallaby sequence were removed (position indicated by asterisk) to facilitate the alignment. As part of this work, we identified a novel mechanism of CFNS pathogenesis, involving the predicted translational read-through of a conserved uORF, leading to repression of translation of EFNB1 from the main dORF. uORFs occur in approximately 140 bp upstream of the start codon. A further uORF found in chicken is also boxed, as are the larger uORFs found in the Xenopus and zebrafish upstream sequences. The zebrafish sequence includes an upstream ATG (underlined) that is in frame with the dORF. Sixteen amino acids of the wallaby sequence were removed (position indicated by asterisk) to facilitate the alignment.
regulating expression of dORFs is increasingly recognized (25). Although minor effects on transcription may occur, the major mechanism by which uORFs act is to decrease the processive readthrough by the 40S ribosomal subunits before they reach the ATG codon of the dORF to initiate translation (24,25). The conservation of the EFNBI uORF in a wide range of mammalian species and birds, and its match to the Kozak consensus, is suggestive of a physiological function in regulating ribosomal loading at the AUG of the EFNBI RNA. However, both the short length of the uORF and the relatively wide separation with the dORF are factors that previous studies suggest would mitigate the negative effect on the dORF (29).

In addition to physiological regulation by uORFs, their pathological mutation represents a rare, but probably underrecognized process reported in at least 14 human diseases. Most previous examples have involved either the disruption of ATG start codons of uORFs, leading to increased translation from the dORF, or the creation of ATG codons creating novel uORFs and leading to reduced translation from the dORF (25). To our knowledge, EFNBI represents the first well-characterized case in which the physiologically reduced translation caused by an uORF (as reflected in the excessive luciferase activity associated with the 1330TTG construct completely lacking the uORF, see Fig. 3C) is further accentuated by a stop-loss mutation increasing the length of the uORF, creating a translation product that is out-of-frame and extends beyond the dORF start codon. Such a mutation is expected to reduce the loading of ribosomes onto the dORF, as reflected in the 49% reduction in luciferase activity (Fig. 3C, compare constructs wt and 1330). By comparison, a superficially analogous stop-loss mutation in U2HR, causing Marie Unna hereditary hypotrichosis, resulted in increased translation of the dORF because, in contrast to the case of EFNBI, the uORF and dORF are in the same frame, thus, yielding a single ORF (30).

In the case of THPO, a mutation creating a premature stop codon in the uORF has been described leading to increased expression of the dORF (thrombocythaemia): this represents the opposite of the mechanism described here (31). Overall, we suspect that stop-loss mutations of uORFs are likely to represent an under-recognized class of hypomorphic mutations, although a search of the Human Gene Mutation Database (HGMD) (see Materials and Methods) did not yield any definite examples.

In conclusion, our work has important practical implications for the molecular diagnosis of CFNS, both in males and females. First, suspected cases negative for mutations or deletions within the coding part of the gene should be screened for variants within the 5′ UTR that may affect translation of EPHRIN-B1. Second, in cases where the diagnosis of CFNS is strongly suspected based on phenotypic assessment, very careful analysis both for variant point mutations and alterations in EFNBI copy number (both decreased and increased) may be required to achieve a definitive diagnosis.

**MATERIALS AND METHODS**

**Patients**

The clinical studies were approved by Oxfordshire Research Ethics Committee B (reference C02.143) and Riverside Research Ethics Committee (reference 09/H07062/20), and informed consent was obtained from all participants by the referring clinicians. Six male subjects with normal male karyotypes (46,XY) exhibiting the characteristic features of CFNS were analysed in this work. DNA was obtained from peripheral blood samples (all subjects), cultured fibroblasts (Subject 1330), buccal brushings (Subjects 3269, 4354 and 3301), saliva (Subjects 1330, 4271 and 4021) and hair roots (Subjects 1330 and 4021) by phenol–chloroform extraction.

**Detection of EFNBI intragenic mutations**

Mutations of EFNBI were detected by a combination of DHPLC, PCR, MPS and MLPA. DHPLC was performed on a Wave 3500HT instrument (Transgenomic, Glasgow, UK). Primers and conditions for all PCR described in this and subsequent sections are provided in Supplementary Material, Table S1 and were designed against NM_004429 (cDNA) and NG_008887 (genomic). MPS was carried out on DNA extracted from Subjects 1330 (blood, fibroblast cell line and hair root), 4271 (blood and saliva) and 4021 (saliva and hair root). Three overlapping PCR products amplified from all tissue samples and spanning 13.7 kb over the entire EFNBI gene (from 1239 bp upstream of the EFNBI ATG to 1590 bp downstream of the stop codon) were pooled in equimolar amounts, and this DNA (total of 3.8 μg) was used to generate a library that was sequenced (single-end reads, 36 bases) using the Solexa platform (Genome Analyzer II, Illumina, San Diego, CA, USA) according to the manufacturer’s instructions. Sequences were aligned to EFNBI using MAQ (http://maq.sourceforge.net/maq-man.shtml) and SNPs called with the MAQ algorithm cnv2mnp. Indel analysis was carried out using Novoalign software (www.Novocraft.com).

**Quantification of mosaic mutations**

Quantification of mosaicism in samples with point mutations was carried out by Pyrosequencing on a PyroMark Q96 MD (Qiagen, Hilden, Germany) of control and patient samples prepared by PCR, with each assay performed on three independent reactions as previously described (14). For each mutation analysed, the dispersion order, and corresponding peaks used to estimate relative levels of normal versus mutant species (separated by/) were as follows: 496C > T: G1A2C3A4T5G6T7A8G9-T10A11G12T13A14G15T16G17G18T19, A4/A8 and T7/T3; c.-95T > G, A1T2G3C4G5C6G7A8G9-G10A11G12G13C14G15C16T17G18A19 and G17/G5; 196C > T, G1A2C3A4G5A6G7G8A9T10G11G12G13C14G15G16A17A18 and G17/G5; 196C > T, G1A2C3A4G5A6G7G8A9T10G11G12G13C14G15G16A17A18 and G17/G5; 196C > T, G1A2C3A4G5A6G7G8A9T10G11G12G13C14G15G16A17A18 and G17/G5; 404C > A, T1G2C3T4A5G6T7C8T9G10A11G12G13A14G15G16T17 and G9/G12.

**Detection of mosaic EFNBI deletions**

Deletions of each of the five exons EFNBI were assayed independently by MLPA (MRC Holland, Amsterdam, The Netherlands) according to protocols available from MRC-Holland: http://www.mrc-holland.com/. Fragments were analysed by capillary electrophoresis using an ABI 3130 containing POP-7 polymer. Peaks were visualized using Gene Mapper v3.7 (Applied Biosystems, Foster City, CA, USA).
3301 was further analysed by hybridization of DNA to a HumanCytoSNP-12 BeadChip (~300 k), according to the manufacturer’s recommendations (Illumina, San Diego, CA, USA).

Isolation of deletion breakpoints by inverse PCR
Two micrograms of DNA (extracted from blood) from Subject 4021 were digested overnight with 40 units of MspI in a total volume of 100 µl. Following phenol–chloroform extraction and precipitation, the DNA was resuspended in 400 µl of 1× ligase buffer and incubated overnight at room temperature with 10 U T4 DNA ligase (Roche, Indianapolis, IN, USA). The DNA was reprecipitated, resuspended in 20 µl of water, and PCR amplification was carried out with primers within exon 2 (E2R1 and E2F2) pointing away from each other. The PCR product was sequenced allowing design of primer 4021BPR for specific amplification (with primer E2F2) of the breakpoint in genomic DNA.

Analysis of uORF by mutagenesis and luciferase assay
The EFNBI 5′ UTR was amplified by PCR, and both normal and −95T > G mutations from Subject 1330 were subcloned into pGEM-T Easy (Promega, Southampton, UK). Site-directed mutagenesis was used to introduce a stop codon (TAG) immediately downstream of the codon containing −95G (mutagenesis primer 1330STOP) and to ablate the uORF ATG codon in the presence of −95G (mutagenesis primer 1330TTC). NheI fragments from the subclones were cloned into the NheI site immediately preceding the Renilla luciferase ORF in the dual-luciferase vector psiCHECK-2 (Promega), a kind gift of David Pagliarini, that had been modified (25), so that Renilla luciferase expression would be driven by the primary ATG codon of EFNBI. All constructs were verified by dyeoxy sequence. Assays were carried out essentially as described (25), except that HEK 293T cells were used and plates were read and analysed using a FLUOstar OPTIMA instrument and software (BMG LABTECH, Aylesbury, UK).

Bioinformatic search for stop-loss in uORFs
The HGMD professional release 2012.1 ([33]; http://www.hgmd.org), was searched for potential stop-loss variants upstream of the initiation codon that had an in-frame ATG start codon within 100 bp upstream of the variant. These sequences were aligned to Hg19 (BLAT, UCSC genome browser) to assess overlap with 5′ UTRs and examined manually. Four bona fide examples were found, but of these, three were common SNPs and in the remaining case, an in-frame stop codon was present upstream of the stop-loss variant.

SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.

ACKNOWLEDGEMENTS
We thank all the subjects and their families for their help with this work, David Pagliarini for providing the luciferase assay construct, Dr Nivaldo Alonso for allowing access to patients of the Plastic Surgery Department, University of São Paulo and Sue Butler and Kevin Clarke for technical assistance.

Conflict of Interest statement. None declared.

FUNDING
This work was supported by the Wellcome Trust (Award Grant Number 090532/Z/09/Z to S.J.L.K.; 075491/Z/04 to L.L. and J.R.; 078666 to A.O.M.W.; 093329 to S.R.F.T. and A.O.M.W.). S.J.L.K. was supported by the NIHR Biomedical Research Centre, Oxford, with funding from the Department of Health’s NIHR Biomedical Research Centres funding scheme. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health. Funding to pay the Open Access publication charges for this article was provided by the Wellcome Trust.

REFERENCES


